Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.

IF 3.5 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY AMB Express Pub Date : 2025-03-12 DOI:10.1186/s13568-025-01837-1

Ann A Elshamy, Sandra K Kamal, Mariam T Mahmoud, Aya M Elhasany, Aya A Shady, Sherok A Mohamed, Hasna A Abd-Elmaaboud, Nour E El-Awady, Rana A Mohamed, Sara A El-Mirghany, Sarraa W El-Hady, Mohamed M Abd-ElRahman, Khaled M Aboshanab

{"title":"Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.","authors":"Ann A Elshamy, Sandra K Kamal, Mariam T Mahmoud, Aya M Elhasany, Aya A Shady, Sherok A Mohamed, Hasna A Abd-Elmaaboud, Nour E El-Awady, Rana A Mohamed, Sara A El-Mirghany, Sarraa W El-Hady, Mohamed M Abd-ElRahman, Khaled M Aboshanab","doi":"10.1186/s13568-025-01837-1","DOIUrl":null,"url":null,"abstract":"<p><p>Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.</p>","PeriodicalId":7537,"journal":{"name":"AMB Express","volume":"15 1","pages":"44"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11904003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AMB Express","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s13568-025-01837-1","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Acinetobacter baumannii is a prevalent clinical pathogen commonly found to be multidrug-resistant (MDR), causing serious to life-threatening infections, particularly hospital-acquired infections with limited therapeutic options. The MDR phenotype developed against this critical pathogen is increasingly developed globally, reaching a pan-drug-resistant phenotype conferring non-susceptibility to all antimicrobials used in its treatment according to the standard guidelines. Therefore, it is critical to develop innovative treatment approaches, such as phage therapy, considering the rise in drug-resistant A. baumannii infections. In this review, we highlight and discuss the up-to-date antimicrobial resistance of A. baumannii, the use of phages, their limitations, and future perspectives in treating A. baumannii infections. In addition, the combination of phages with antimicrobials, preclinical and clinical studies including pharmacokinetics and pharmacodynamics properties have been discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

噬菌体治疗耐多药鲍曼不动杆菌的最新研究进展。

鲍曼不动杆菌是一种常见的临床病原体，通常被发现具有多重耐药（MDR），导致严重到危及生命的感染，特别是治疗选择有限的医院获得性感染。针对这一关键病原体开发的耐多药表型在全球范围内日益发展，达到泛耐药表型，根据标准指南，对其治疗中使用的所有抗菌素都不敏感。因此，考虑到耐药鲍曼杆菌感染的增加，开发诸如噬菌体治疗等创新治疗方法至关重要。在这篇综述中，我们强调并讨论了鲍曼不动杆菌的最新耐药性，噬菌体的使用，它们的局限性，以及治疗鲍曼不动杆菌感染的未来前景。此外，还讨论了噬菌体与抗菌素的结合，临床前和临床研究，包括药代动力学和药效学特性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

AMB Express BIOTECHNOLOGY & APPLIED MICROBIOLOGY-

CiteScore

7.20

自引率

2.70%

发文量

141

审稿时长

13 weeks

期刊介绍： AMB Express is a high quality journal that brings together research in the area of Applied and Industrial Microbiology with a particular interest in ''White Biotechnology'' and ''Red Biotechnology''. The emphasis is on processes employing microorganisms, eukaryotic cell cultures or enzymes for the biosynthesis, transformation and degradation of compounds. This includes fine and bulk chemicals, polymeric compounds and enzymes or other proteins. Downstream processes are also considered. Integrated processes combining biochemical and chemical processes are also published.